Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Trial · NCT00371683
Results by group178
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 178
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects | Apixaban 2.5mg BID | 8.99 | 95% Confidence Interval 7.47 to 10.79 | percentage of participants | |
| Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects | Enoxaparin 30 mg SC Injection q 12 Hours | 8.85 | 95% Confidence Interval 7.33 to 10.66 | percentage of participants | |
| Event Rate of Composite of Adjudicated Proximal DVT, Non-Fatal PE and All-Cause Death With Onset During the Intended Treatment Period PE and All-cause Death During the Intended Treatment Period | Apixaban 2.5mg BID | 2.05 | 95% Confidence Interval 1.39 to 3.01 | percentage of participants | |
| Event Rate of Composite of Adjudicated Proximal DVT, Non-Fatal PE and All-Cause Death With Onset During the Intended Treatment Period PE and All-cause Death During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 1.64 | 95% Confidence Interval 1.06 to 2.55 | percentage of participants | |
| Event Rate of Adjudicated VTE / VTE-related Death With Onset During the Treatment Period | Apixaban 2.5mg BID | 8.91 | 95% Confidence Interval 7.40 to 10.71 | percentage of participants | |
| Event Rate of Adjudicated VTE / VTE-related Death With Onset During the Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 8.61 | 95% Confidence Interval 7.10 to 10.40 | percentage of participants | |
| Event Rate for Participants With Proximal DVT/Non-Fatal PE/ VTE-Related Death With Onset During the Intended Treatment Period | Apixaban 2.5mg BID | 1.97 | 95% Confidence Interval 1.33 to 2.92 | percentage of participants | |
| Event Rate for Participants With Proximal DVT/Non-Fatal PE/ VTE-Related Death With Onset During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 1.40 | 95% Confidence Interval 0.86 to 2.26 | percentage of participants | |
| Event Rate for Total Participants With Adjudicated VTE/All-Cause Death With Onset During the Intended Treatment Period | Apixaban 2.5mg BID | 2.13 | 95% Confidence Interval 1.46 to 3.10 | percentage of participants | |
| Event Rate for Total Participants With Adjudicated VTE/All-Cause Death With Onset During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 1.97 | 95% Confidence Interval 1.32 to 2.94 | percentage of participants | |
| Event Rate for Total Participants With VTE/ VTE-Related Death With Onset During the Intended Treatment Period | Apixaban 2.5mg BID | 2.05 | 95% Confidence Interval 1.39 to 3.01 | percentage of participants | |
| Event Rate for Total Participants With VTE/ VTE-Related Death With Onset During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 1.73 | 95% Confidence Interval 1.12 to 2.65 | percentage of participants | |
| Event Rate for Participants With All-Cause Death During the Intended Treatment Period | Apixaban 2.5mg BID | 0.19 | 95% Confidence Interval 0.04 to 0.59 | percentage of participants | |
| Event Rate for Participants With All-Cause Death During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 0.19 | 95% Confidence Interval 0.04 to 0.59 | percentage of participants | |
| Event Rate for Participants With VTE-Related Death With Onset During the Intended Treatment Period | Apixaban 2.5mg BID | 0.13 | 95% Confidence Interval 0.00 to 0.49 | percentage of participants | |
| Event Rate for Participants With VTE-Related Death With Onset During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 0.00 | 95% Confidence Interval 0.00 to 0.30 | percentage of participants | |
| Event Rate for Participants With Symptomatic VTE/ All-Cause Death With Onset During the Intended Treatment Period | Apixaban 2.5mg BID | 1.25 | 95% Confidence Interval 0.80 to 1.94 | percentage of participants | |
| Event Rate for Participants With Symptomatic VTE/ All-Cause Death With Onset During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 1.00 | 95% Confidence Interval 0.61 to 1.64 | percentage of participants | |
| Event Rate for Participants With Symptomatic VTE/ VTE-Related Death With Onset During the Intended Treatment Period | Apixaban 2.5mg BID | 1.19 | 95% Confidence Interval 0.75 to 1.87 | percentage of participants | |
| Event Rate for Participants With Symptomatic VTE/ VTE-Related Death With Onset During the Intended Treatment Period | Enoxaparin 30 mg SC Injection q 12 Hours | 0.81 | 95% Confidence Interval 0.46 to 1.41 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00371683/results